0 Σχόλια
0 Μοιράστηκε
4 Views
0 Προεπισκόπηση
Αναζήτηση
Ανακάλυψε νέους ανθρώπους, δημιούργησε νέες συνδέσεις και κάνε καινούργιους φίλους
-
Παρακαλούμε συνδέσου στην Κοινότητά μας για να δηλώσεις τι σου αρέσει, να σχολιάσεις και να μοιραστείς με τους φίλους σου!
-
JPMorgan cuts DuPont de Nemours Inc. (DD) to neutral, saying the restocking lift has largely played outJPMorgan analyst Chigusa Katoku lowered her DuPont de Nemours Inc. (DD) target to $145 from $172, citing slower short-cycle restocking, months after a second quarter that beat the company's own guidance. JPMorgan analyst Chigusa Katoku cut DuPont de Nemours Inc. (DD) to neutral from overweight on Friday and lowered her price target to $145 from $172. Investing.com reported the call, which...0 Σχόλια 0 Μοιράστηκε 9 Views 0 Προεπισκόπηση
-
Natera (NTRA) draws a Buy and a $475 target as Roth/MKM bets on cancer residual disease testsRoth/MKM started coverage of Natera, Inc. (NTRA) at Buy with a $475 target, pointing to wider use of its minimal residual disease blood tests, firmer pricing and a 2027 early detection study readout. Roth/MKM started coverage of Natera, Inc. (NTRA) on Friday, October 23, 2026, with a Buy rating and a $475 price target, Investing.com reported. The firm built its case on the company's cancer...0 Σχόλια 0 Μοιράστηκε 6 Views 0 Προεπισκόπηση
-
Piper Sandler cuts Globe Life (GL) to Neutral as Medicare Supplement claims cloud its 2027 outlookPiper Sandler moved Globe Life Inc. (GL) to Neutral from Overweight and cut its target to $165 from $200, citing medical claims and 2027 guidance after a quarter in which health benefits rose 19%. Piper Sandler downgraded Globe Life Inc. (GL) to Neutral from Overweight on Friday and cut its price target to $165 from $200, according to Investing.com. The firm said the insurer lost much of the...0 Σχόλια 0 Μοιράστηκε 6 Views 0 Προεπισκόπηση